Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

This study has been completed.
Information provided by (Responsible Party):
University of Arkansas Identifier:
First received: May 31, 2012
Last updated: September 29, 2015
Last verified: September 2015
Results First Received: August 12, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Multiple Myeloma
Intervention: Drug: Revlimid

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Revlimid Revlimid: 10 mg/day in the morning same time each day
Observation No treatment

Participant Flow:   Overall Study
    Revlimid   Observation
STARTED   25   17 
COMPLETED   25   17 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Revlimid Revlimid: 10 mg/day in the morning same time each day
Observation No treatment
Total Total of all reporting groups

Baseline Measures
    Revlimid   Observation   Total
Overall Participants 
[units: participants]
 25   17   42 
[units: participants]
<=18 years   0   0   0 
Between 18 and 65 years   14   11   25 
>=65 years   11   6   17 
[units: participants]
Female   9   5   14 
Male   16   12   28 
Race/Ethnicity, Customized 
[units: participants]
White   24   17   41 
Other   1   0   1 

  Outcome Measures

1.  Primary:   Progression Free Survival (PFS)   [ Time Frame: 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Bart Barlogie
Organization: University of Arkansas for Medical Sciences
phone: 526-6990 ext 2420

Responsible Party: University of Arkansas Identifier: NCT01621672     History of Changes
Other Study ID Numbers: 110468
Study First Received: May 31, 2012
Results First Received: August 12, 2015
Last Updated: September 29, 2015
Health Authority: United States: Institutional Review Board